The impact of age on antimullerian hormone serum level in women attending chemotherapy Unit for primary breast cancer

The aim of the study is to evaluate serum level of Anti-Mullerian Hormone in patients with primary breast cancer proposed to have chemotherapy and to study the effect age on Anti-Mullerian Hormone and menstrual cycle pattern after chemotherapy. In reproductive-aged breast cancer survivors, there is a need for “real-time” biomarkers of post-chemotherapy ovarian function. This prospective cohort study had been conducted upon one hundred twenty women, sixty women as a patient group (n = 60), who are newly diagnosed with primary breast cancer and Sixty women as a control group (n = 60). Their ages between (21 and 41) years. Patients were subgrouped according to age as ≤35 and >35 years. There were significant differences between patients and control groups regarding BMI,regularity of menstrual cycle (P < 0.05). There were significant differences between antimullerian hormone before and after the first dose of chemotherapy, in all age groups (p < 0.05). There was a significant difference in antimullerian hormone before and after administration of second dose of chemotherapy in those who are less or equal to 35 years. But no such difference in antimullerian hormone after the second dose of chemotherapy in those who were above 35 years. Serum AMH is a convenient and sensitive indicator of follicular depletion and recovery in young women during and after chemotherapy, this needs to be confirmed by larger size group.